CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge

Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally,...

Descripción completa

Detalles Bibliográficos
Autores principales: de Melo Gagliato, Debora, C Buzaid, Antonio, Perez-Garcia, Jose Manuel, Llombart, Antonio, Cortes, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563142/
https://www.ncbi.nlm.nih.gov/pubmed/32882980
http://dx.doi.org/10.3390/cancers12092480

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563142/
https://www.ncbi.nlm.nih.gov/pubmed/32882980
http://dx.doi.org/10.3390/cancers12092480

Ejemplares similares